Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMP1734 · 1 trial · 1 indication
Number of subjects reporting adverse events or serious adverse events which include any abnormal clinical events, laboratory assessments outside of normal clinical range, abnormal vital signs observed, and any abnormal ECG parameters
Number of patients that experience a DLT or any toxicity which occurs from the time of the first dose of study drug until the end of cycle 1, which is deemed unrelated to the disease.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | IMP1734 monotherapy; oral tablet(s) daily (except for the single-dose period). The maximum trial duration is 3 years after the last participant's first treatment in the trial. |
| Name | Type | Description |
|---|---|---|
| IMP1734 | DRUG | PARP1 selective inhibitor |
Key Inclusion Criteria * Breast cancer; must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+, * HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one pri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IMP1734 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development as a first-in-human study in participants with advanced solid tumors.
IMP1734 targets PARP1, a protein involved in DNA repair. By selectively inhibiting PARP1, the drug aims to interfere with the repair mechanisms of cancer cells, potentially leading to their death. This mechanism is being studied in the context of advanced solid tumors.
IMP1734 is being developed by Eikon Therapeutics, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of IMP1734 in patients with advanced solid tumors.
IMP1734 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy.
IMP1734 is being studied in a Phase 1 clinical trial with the identifier NCT06253130. This first-in-human study is recruiting 156 participants with advanced solid tumors across multiple countries, including the United States, Australia, Canada, China, Denmark, France, South Korea, and Spain.
IMP1734 is a selective PARP1 inhibitor, which distinguishes it from other PARP inhibitors that may target multiple PARP family members. Its selectivity for PARP1 is a key feature being investigated in the ongoing Phase 1 trial for advanced solid tumors.